158 related articles for article (PubMed ID: 10945769)
1. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy.
Chen Y; Yu DC; Charlton D; Henderson DR
Hum Gene Ther; 2000 Jul; 11(11):1553-67. PubMed ID: 10945769
[TBL] [Abstract][Full Text] [Related]
2. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.
Rodriguez R; Schuur ER; Lim HY; Henderson GA; Simons JW; Henderson DR
Cancer Res; 1997 Jul; 57(13):2559-63. PubMed ID: 9205053
[TBL] [Abstract][Full Text] [Related]
3. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
4. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.
Harvey BG; Hackett NR; El-Sawy T; Rosengart TK; Hirschowitz EA; Lieberman MD; Lesser ML; Crystal RG
J Virol; 1999 Aug; 73(8):6729-42. PubMed ID: 10400771
[TBL] [Abstract][Full Text] [Related]
5. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model.
Tsai V; Johnson DE; Rahman A; Wen SF; LaFace D; Philopena J; Nery J; Zepeda M; Maneval DC; Demers GW; Ralston R
Clin Cancer Res; 2004 Nov; 10(21):7199-206. PubMed ID: 15534093
[TBL] [Abstract][Full Text] [Related]
6. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.
Särkioja M; Pesonen S; Raki M; Hakkarainen T; Salo J; Ahonen MT; Kanerva A; Hemminki A
Gene Ther; 2008 Jun; 15(12):921-9. PubMed ID: 18401431
[TBL] [Abstract][Full Text] [Related]
7. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy.
Moffatt S; Hays J; HogenEsch H; Mittal SK
Virology; 2000 Jun; 272(1):159-67. PubMed ID: 10873758
[TBL] [Abstract][Full Text] [Related]
8. Overcoming the immune response to permit ex vivo gene therapy for spine fusion with human type 5 adenoviral delivery of the LIM mineralization protein-1 cDNA.
Kim HS; Viggeswarapu M; Boden SD; Liu Y; Hair GA; Louis-Ugbo J; Murakami H; Minamide A; Suh DY; Titus L
Spine (Phila Pa 1976); 2003 Feb; 28(3):219-26. PubMed ID: 12567021
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial.
Somanathan S; Calcedo R; Wilson JM
Mol Ther; 2020 Mar; 28(3):784-793. PubMed ID: 32035027
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts.
Gahéry-Ségard H; Juillard V; Gaston J; Lengagne R; Pavirani A; Boulanger P; Guillet JG
Eur J Immunol; 1997 Mar; 27(3):653-9. PubMed ID: 9079805
[TBL] [Abstract][Full Text] [Related]
12. Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector.
Myhre S; Henning P; Granio O; Tylö AS; Nygren PA; Olofsson S; Boulanger P; Lindholm L; Hong SS
Gene Ther; 2007 Feb; 14(4):376-81. PubMed ID: 17036056
[TBL] [Abstract][Full Text] [Related]
13. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.
O'Riordan CR; Lachapelle A; Delgado C; Parkes V; Wadsworth SC; Smith AE; Francis GE
Hum Gene Ther; 1999 May; 10(8):1349-58. PubMed ID: 10365665
[TBL] [Abstract][Full Text] [Related]
14. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.
Holterman L; Vogels R; van der Vlugt R; Sieuwerts M; Grimbergen J; Kaspers J; Geelen E; van der Helm E; Lemckert A; Gillissen G; Verhaagh S; Custers J; Zuijdgeest D; Berkhout B; Bakker M; Quax P; Goudsmit J; Havenga M
J Virol; 2004 Dec; 78(23):13207-15. PubMed ID: 15542673
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse.
Paielli DL; Wing MS; Rogulski KR; Gilbert JD; Kolozsvary A; Kim JH; Hughes J; Schnell M; Thompson T; Freytag SO
Mol Ther; 2000 Mar; 1(3):263-74. PubMed ID: 10933942
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.
Bradley RR; Maxfield LF; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
J Virol; 2012 Jan; 86(2):1267-72. PubMed ID: 22072746
[TBL] [Abstract][Full Text] [Related]
17. Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues.
Yang L; Guo J; Wang J; Wan S; Yang S; Wang R; Chen W; Peng G; Fang D
Int Immunopharmacol; 2012 May; 13(1):37-45. PubMed ID: 22406047
[TBL] [Abstract][Full Text] [Related]
18. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
Wildner O; Morris JC
Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
[TBL] [Abstract][Full Text] [Related]
19. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.
Gahéry-Ségard H; Farace F; Godfrin D; Gaston J; Lengagne R; Tursz T; Boulanger P; Guillet JG
J Virol; 1998 Mar; 72(3):2388-97. PubMed ID: 9499099
[TBL] [Abstract][Full Text] [Related]
20. Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy.
Breidenbach M; Rein DT; Wang M; Nettelbeck DM; Hemminki A; Ulasov I; Rivera AR; Everts M; Alvarez RD; Douglas JT; Curiel DT
Hum Gene Ther; 2004 May; 15(5):509-18. PubMed ID: 15144580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
